Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
March 13, 2025 02:00 ET
|
Pharming Group N.V.
Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total...
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
March 04, 2025 09:15 ET
|
Pharming Group N.V.
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of...
Pharming Group to participate in March investor conference
February 28, 2025 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
February 27, 2025 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year...
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
February 20, 2025 16:00 ET
|
Pharming Group N.V.
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to...
Pharming Group to participate in February investor conference
February 10, 2025 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
February 07, 2025 16:00 ET
|
Pharming Group N.V.
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to...
Pharming Group to convene Extraordinary General Meeting of Shareholders
January 21, 2025 12:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of...
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
January 21, 2025 01:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice...
Pharming announces public cash offer to the shareholders of Abliva AB
December 15, 2024 13:45 ET
|
Pharming Group N.V.
Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim...